SPL 3.26% $2.08 starpharma holdings limited

Just in case it hasn't sunk in

  1. 9,703 Posts.
    lightbulb Created with Sketch. 820
    AstraZeneca collaborations with Starpharma

    *1st candidate DEP AZD0466 is currently in  human phase 1 clinical trials.

    AstraZeneca fund all costs to market.

    As the molecule advances through clinical trials Starpharma will receive milestone payments of approximately AU$91 million.

    Post clinical trials to regulatory approval Starpharma will receive a further AU$91 million

    Starpharma has stated escalating received royalties over life of patent could amount to AU$3.5 billion

    *2nd candidate undisclosed is currently being developed jointly in pre-clinical trials. This candidate  (if going to human trials), will generate AU$137 million in milestone payments plus royalties once marketed

    *3rd candidate is being investigated in-house by Starpharma. This molecule is currently sold globally generating over a US$1 billion (blockbuster drug). The drug is off-patent (recently 2019). If AstraZeneca decide to take up option and develop it to regulatory approval, it will provide milestone payments of AU$137 million to Starpharma with royalty stream on sales. Please note that Starpharma have been working on this molecule in collaboration with AstraZeneca previous to it being further investigated by Starpharma in-house. If AstraZeneca take up option they will hand over a payment of over AU$7 million
    Last edited by antibotter: 31/01/20
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Mkt cap ! $844.5M
Open High Low Value Volume
$2.12 $2.14 $2.07 $1.405M 670.1K

Buyers (Bids)

No. Vol. Price($)
3 14007 $2.08

Sellers (Offers)

Price($) Vol. No.
$2.10 1850 1
View Market Depth
Last trade - 16.10pm 26/02/2021 (20 minute delay) ?
-0.070 ( 2.27 %)
Open High Low Volume
$2.10 $2.14 $2.07 111797
Last updated 15.58pm 26/02/2021 (live) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.